Multistep Process of Establishing Carcinoma Metastases

Czech version

Authors: E. Ondroušková; L. Sommerová; R. Hrstka
Authors‘ workplace: Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2016; 29(Supplementum 4): 12-17
Category: Review
doi: https://doi.org/10.14735/amko20164S12

Overview

Background:
Dissemination of cancer cells from the primary tumor and establishment of therapy-resistant distant metastases is the most common cause of human cancer deaths. The primary tumor consists of a heterogeneous population of cancer cells that have to overcome activity of the immune system, insufficient delivery of nutrients and oxygen, chemotherapy, radiotherapy etc. that lead to the selection of resistant and plastic cancer cells. Another selection pressure during metastatic spread gives rise to resistant subpopulations of cells, capable of surviving and proliferating in the hostile microenvironment of distant tissues.

Aim:
In this article, individual steps of the metastatic cascade are described as well as the mechanisms and signaling pathways that cancer cells use to deal with them. Metastatic process is generally inefficient and only very few cells released from the primary tumor develop into metastases. This success is enabled by pro-metastatic mutations, accumulated due to the selection pressure and also by cooperation of non-transformed cells that secrete supporting factors.

Conclusion:
Recent advances in research provide deeper insights into the complex processes that lead to formation and dissemination of cancer cells. Deciphering the key points of metastatic cascade and principles of its regulation will perhaps lead to development of efficient therapeutics targeting metastatic cells.

Key words:
metastasis – carcinoma – vascular endothelial growth factor A – epithelial-mesenchymal transitio

This work was supported by the project MEYS – NPS I – LO1413.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
6. 5. 2016

Accepted:
19. 5. 2016

Sources

1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127 (4): 679–695.

2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9 (4): 274–284. doi: 10.1038/nrc2622.

3. Kozłowski J, Kozłowska A, Kocki J. Breast cancer metastasis – insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Dosw (online) 2015; 69: 447–451.

4. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147 (2): 275–292. doi: 10.1016/j.cell.2011.09.024.

5. Tarin D, Price JE, Kettlewell MG et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984; 44 (8): 3584–3592.

6. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2 (8): 563–572.

7. Gould Rothberg BE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat 2006; 100 (2): 139–148.

8. Heerboth S, Housman G, Leary M et al. EMT and tumor metastasis. Clin Transl Med 2015; 4: 6–19. doi: 10.1186/s40169-015-0048-3.

9. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res 2005; 65 (24): 11230–11235.

10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7 (2): 131–142.

11. Zhang L, Huang G, Li X et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor-1alpha in hepatocellular carcinoma. BMC Cancer 2013; 13: 108–117. doi: 10.1186/1471-2407-13-108.

12. Kumar S, Das A, Sen S. Extracellular matrix density promotes EMT by weakening cell-cell adhesions. Mol Biosyst 2014; 10 (4): 838–850. doi: 10.1039/c3mb70431a.

13. Sanchez-Tillo E, Liu Y, de Barrios O et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012; 69 (20): 3429–3456. doi: 10.1007/s00018-012-1122-2.

14. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278 (1): 16–27. doi: 10.1111/j.1742-4658.2010.07919.x.

15. Almholt K, Johnsen M. Stromal cell involvement in cancer. Recent Results Cancer Res 2003; 162: 31–42.

16. Sloane BF, Sameni M, Podgorski I et al. Functional imaging of tumor proteolysis. Annu Rev Pharmacol Toxicol 2006; 46: 301–315.

17. Taddei ML, Giannoni E, Morandi A et al. Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells. Cell Commun Signal 2014; 12: 24–36. doi: 10.1186/1478-811X-12-24.

18. Kumar S, Kapoor A, Desai S et al. Proteolytic and non-proteolytic regulation of collective cell invasion: tuning by ECM density and organization. Sci Rep 2016; 6: 19905–19922. doi: 10.1038/srep19905.

19. Jolly MK, Boareto M, Huang B et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol 2015; 5: 155–174. doi: 10.3389/fonc.2015.00155.

20. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013; 27 (20): 2192–2206. doi: 10.1101/gad.225334.113.

21. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 2011; 37 (1): 63–74. doi: 10.1016/j.ctrv.2010.05. 001.

22. Reymond N, d‘Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer 2013; 13 (12): 858–870. doi: 10.1038/nrc3628.

23. Khuon S, Liang L, Dettman RW et al. Myosin light chain kinase mediates transcellular intravasation of breast cancer cells through the underlying endothelial cells: a three-dimensional FRET study. J Cell Sci 2010; 123 (Pt 3): 431–440. doi: 10.1242/jcs.053793.

24. Barnes JM, Nauseef JT, Henry MD. Resistance to fluid shear stress is a conserved biophysical property of malignant cells. PLoS One 2012; 7 (12): e50973. doi: 10.1371/journal.pone.0050973.

25. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11 (2): 123–134. doi: 10.1038/nrc3004.

26. Liu Y, Jiang P, Capkova K et al. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res 2011; 71 (20): 6492–6502. doi: 10.1158/0008-5472.CAN-11-1145.

27. Camerer E, Qazi AA, Duong DN et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104 (2): 397–401.

28. Palumbo JS, Talmage KE, Massari JV et al. Platelets and fibrin (ogen) increase metastatic potential by im- peding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105 (1): 178–185.

29. Karpatkin S, Pearlstein E, Ambrogio C et al. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81 (4): 1012–1019.

30. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1889; 8 (2): 98–101.

31. Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis 1992; 10 (3): 191–199.

32. Kienast Y, von Baumgarten L, Fuhrmann M et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16 (1): 116–122. doi: 10.1038/nm.2072.

33. Lorusso G, Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012; 22 (3): 226–233. doi: 10.1016/j.semcancer.2012.03.007.

34. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28 (20): 3271–3277. doi: 10.1200/JCO.2009.25.9820.

35. Soni A, Ren Z, Hameed O et al. Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 2015; 143 (4): 471–478. doi: 10.1309/AJCPYO5FSV3UPEXS.

36. Furusato B, Mohamed A, Uhlen M et al. CXCR4 and cancer. Pathol Int 2010; 60 (7): 497–505. doi: 10.1111/j.1440- 1827.2010.02548.x.

37. Cavallaro S. CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain. Int J Mol Sci 2013; 14 (1): 1713–1727. doi: 10.3390/ijms14011713.

38. Li YM, Pan Y, Wei Y et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6 (5): 459–469.

39. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410 (6824): 50–56.

40. Sarvaiya PJ, Guo D, Ulasov I et al. Chemokines in tumor progression and metastasis. Oncotarget 2013; 4 (12): 2171–2185.

41. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006; 79 (4): 639–651.

42. Géraud C, Koch PS, Damm F et al. The metastatic cycle: metastatic niches and cancer cell dissemination. J Dtsch Dermatol Ges 2014; 12 (11): 1012–1019. doi: 10.1111/ddg.12451.

43. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012; 2012: 676731–676741.

44. Miles FL, Pruitt FL, van Golen KL et al. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis 2008; 25 (4): 305–324.

45. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007; 14 (4): 377–386.

46. Brown DM, Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004; 5 (4): 365–374.

47. Weis S, Cui J, Barnes L et al. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004; 167 (2): 223–229.

48. Padua D, Zhang XH, Wang Q et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133 (1): 66–77. doi: 10.1016/j.cell.2008.01.046.

49. Tichet M, Prod‘Homme V, Fenouille N et al. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun 2015; 6: 6993–7008. doi: 10.1038/ncomms7993.

50. Qian BZ, Li J, Zhang H et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475 (7355): 222–225. doi: 10.1038/nature10138.

51. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438 (7069): 820–827.

52. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev 2013; 32 (3–4): 449–464. doi: 10.1007/s10555-013-9420-1.

53. Costa-Silva B, Aiello NM, Ocean AJ et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 2015; 17 (6): 816–826. doi: 10.1038/ncb3169.

54. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8 (5): 329–340. doi: 10.1038/nrc2375.

55. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 1999; 91 (1): 80–85.

56. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009; 106 (25): 10290–10295. doi: 10.1073/pnas.0904227106.

57. Barkan D, El Touny LH, Michalowski AM et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 2010; 70 (14): 5706–5716. doi: 10.1158/0008-5472.CAN-09-2356.

58. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell 2013; 155 (4): 750–764. doi: 10.1016/j.cell.2013.10.029.

59. Zhang XH, Wang Q, Gerald W et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16 (1): 67–78. doi: 10.1016/j.ccr.2009.05.017.

60. Chen Q, Zhang XH, Massagué J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011; 20 (4): 538–549. doi: 10.1016/j.ccr.2011.08.025.

61. Holmgren L, O‘Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1 (2): 149–153.

62. Gao H, Chakraborty G, Lee-Lim AP et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012; 150 (4): 764–779. doi: 10.1016/j.cell. 2012.06.035.

63. Oskarsson T, Acharyya S, Zhang XH et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17 (7): 867–874. doi: 10.1038/nm.2379.

64. Malanchi I, Santamaria-Martínez A, Susanto E et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481 (7379): 85–89. doi: 10.1038/nature10694.

65. Barkan D, Chambers AF. Beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011; 17 (23): 7219–7223. doi: 10.1158/1078-0432.CCR-11-0642.

66. McAllister SS, Gifford AM, Greiner AL et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133 (6): 994–1005. doi: 10.1016/j.cell. 2008.04.045.

67. Hiratsuka S, Duda DG, Huang Y et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1) -positive cells. Proc Natl Acad Sci U S A 2011; 108 (1): 302–307. doi: 10.1073/pnas.1016917108.